The Migraine Drugs Market is being driven by Increasing number of patients suffering from migraine
The Migraine Drugs Market is expected to grow at a CAGR of 6.36% during 2023 and 2028. During this period, the market is also expected to show a growth of USD 1.34 billion. The global migraine drugs market is witnessing significant growth due to the increasing focus on the development of migraine-preventive drugs. Manufacturers are prioritizing the production of these preventive medications to inhibit the onset of migraines. Some of these drugs function by modifying brain chemicals, thereby minimizing the likelihood of migraine occurrence. For instance, triptans, a class of migraine-preventive drugs, restrict the dilation of blood vessels, thereby obstructing the release of the enzyme responsible for inflammation. The emergence of novel migraine drugs is transforming the landscape of pharmacological migraine prevention, offering potential solutions to reduce attack frequency and severity.
Get more information on Migraine Drugs Market by requesting a sample report
The market is segmented based on segments_for_ai.nslist
According to Technavio, There are several factors that are causing the market to flourish during the forecast period, which are as follows:
However, the market also witnesses some limitations, which are as follows:
Rich Experience: 20+ years leading global market research, trusted insights across industries.
Unlock Business Potential with Technavio: Maximize ROI with Technavio's tailored market research: deep dives and actionable insights.
Your Guide to Market Success: Empower your business with Technavio's market research and future-proof your decisions.
Market Scope |
|
Report Coverage |
Details |
Page number |
168 |
Base year |
2023 |
Historic period |
2018-2022 |
Forecast period |
2024-2028 |
Growth momentum & CAGR |
Accelerate at a CAGR of 6.36% |
Market growth 2024-2028 |
USD 1.34 billion |
Market structure |
Fragmented |
YoY growth 2023-2024(%) |
6.22 |
Key countries |
US, Canada, Germany, China, and Japan |
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Find out which segment is leading the market by accessing the free PDF report
The Migraine Drugs Market caters to the demand for pain-relieving medications used in managing the neurological medical disease, Migraine. Factors driving market growth include increasing patient awareness, sedentary lifestyles among the younger generation, and the prevalence of sensory disturbances such as photophobia, phonophobia, and osmophobia. These drugs include analgesics, antipsychotics, anticonvulsant drugs, and neurological therapeutics. Migraines can cause nausea, vomiting, loss of appetite, and neurological manifestations like virus-induced neurological conditions, cardiac diseases, pulmonary diseases, and vascular diseases. The drugs act on the nervous system, specifically the olfactory groove, and can enter the bloodstream to alleviate symptoms.
The global migraine drugs market is a significant segment of the larger pharmaceuticals industry within the healthcare sector, according to Technavio's market research. The pharmaceuticals market encompasses entities involved in the research and development (R&D) or manufacturing of various drug categories, including generic and non-generic medicines, as well as veterinary drugs. The healthcare industry's overall size is determined by Technavio by aggregating the revenues generated by suppliers of medical equipment, consumables, pharmaceuticals, biotechnology, and life sciences tools and services. Factors driving the expansion of the global pharmaceuticals market include an aging population, with the number of individuals over 60 years projected to rise substantially, and the increasing prevalence of migraines, particularly among younger generations and sedentary lifestyles. This market growth is further fueled by the demand for effective treatments for neurological medical conditions like migraines, leading to a surge in the development and commercialization of analgesics and antipsychotics for migraine relief.. Industries are leveraging the products belonging to the market for customer engagement, transactional notifications, and promotional offers.
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
Safe and Secure SSL Encrypted